Cerebrolysin is unusual among the compounds in this library: it is not a single peptide but a standardized mixture of low-molecular-weight neuropeptides and free amino acids produced from purified brain proteins. It is among the most extensively studied neurotrophic preparations in the world.
Mechanism under investigation
Cerebrolysin is described as neurotrophic and neuroprotective, mimicking the action of endogenous growth factors such as NGF and BDNF to support neuronal survival, plasticity, and repair. This mechanism underlies its study across a range of neurological conditions.
Research applications
- Acute ischemic stroke and post-stroke recovery.
- Vascular dementia and Alzheimer’s research.
- Traumatic brain injury and neurorehabilitation.
Clinical outlook
Cerebrolysin has one of the deepest clinical records of any neuropeptide product — dozens of registered human trials. Randomized, placebo-controlled studies have investigated it in stroke and dementia (NCT01787123), and active Phase 4 research continues, including work on post-stroke language recovery in aphasia (NCT06897176). It is already approved and used clinically in numerous countries across Europe and Asia — a real example of a neuropeptide preparation that has completed much of the bench-to-bedside journey, even as researchers continue to define exactly where it helps most.
References
- Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin
- Safety profile of Cerebrolysin: clinical experience from dementia and stroke trials
- [Therapy prospects for post-stroke aphasia]
- Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial
- Diabetes and the brain: issues and unmet needs
